EMERCell has been created in February 2013 and is located at the IRMB (Institute of Regenerative Medicine & Biotherapies) at the University Hospital of Saint-Eloi, Montpellier, France.
EMERCell is an emerging independently funded biotechnology company, developing projects in the fields of immunotherapy and cell therapy until pharmaceutical development phases.
The company strategy is firstly based on the development of a cell immunotherapy product in oncology: NK-001, a new Advanced Therapy Medicinal Product (ATMP) using a patented process to amplify and activate allogeneic Natural Killer (NK) cells, to be used in association with monoclonal antibodies. This generic tool is currently evaluated in oncohematology.
EMERCell has currently 5 employees and many collaborators and specialist consultants to cover the different areas of this first project. EMERCell is also collaborating with various academic and industrial partners.